Priority Review means that FDA aims to take action on an application within six months, compared to 10 months under standard review. A Priority Review designation directs attention and resources to evaluate drugs that would significantly improve the treatment, diagnosis, or prevention of serious conditions.8 Apr 2022
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$7.84 |
Change
-0.120(1.51%) |
Mkt cap ! $5.687B | |||
| Open | High | Low | Value | Volume |
| $7.99 | $7.99 | $7.83 | $7.705M | 980.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24483 | $7.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.85 | 282 | 1 |
View Market Depth
| Last trade - 16.14pm 08/08/2025 (20 minute delay) ? |
| A2M (ASX) Chart |